Alemtuzumab (marketed as Campath and currently under further development as Lemtrada.

Treating Multiple Sclerosis in 2013

DOCTORS DISCUSS EVERY MS TREATMENT NOW AVAILABLE INCLUDING:

(1) Alemtuzumab (marketed as Campath and currently under further development as LEMTRADA)
(2) teriflunomide (AUBAGIO)
(3) dimethyl fumarate (TECFIDERA)
(4) FINGOLIMOD
(5) TYSABRI (natalizumab)

Treating Multiple Sclerosis in 2013

DOCTORS DISCUSS EVERY MS TREATMENT NOW AVAILABLE INCLUDING:

(1) Alemtuzumab (marketed as Campath and currently under further development as LEMTRADA)
(2) teriflunomide (AUBAGIO)
(3) dimethyl fumarate (TECFIDERA)
(4) FINGOLIMOD
(5) TYSABRI (natalizumab)

BREAKING NEWS

FDA Investigates PML-Brain
Infection Gilenya Case

Oct. 18, 2013 -- The FDA is continuing to investigate a possible link between the multiple sclerosis drug Gilenya (fingolimod) and a case of a rare brain infection in a European patient.